Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL1535 (Hydroxychloroquine, Polirreumin) |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
α1D-adrenoceptor/Alpha-1d adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL223] [GtoPdb: 24] [UniProtKB: P25100] | ||||||||
ChEMBL | DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) | B | 5.63 | pKi | 2346 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) | B | 5.32 | pIC50 | 4772 | nM | IC50 | DrugMatrix in vitro pharmacology data |
α2A-adrenoceptor/Alpha-2a adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1867] [GtoPdb: 25] [UniProtKB: P08913] | ||||||||
ChEMBL | Activity of compound against Alpha-2A (ADRA2A) adrenergic receptor by displacement of [3H]-rauwolscine | B | 5.19 | pKi | 6456.54 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
α2B-adrenoceptor/Alpha-2b adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1942] [GtoPdb: 26] [UniProtKB: P18089] | ||||||||
ChEMBL | Activity of compound against Alpha 2B (ADRA2B) adrenergic receptor by displacement of [3H]-rauwolscine | B | 4.14 | pKi | 72443.6 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
α2C-adrenoceptor/Alpha-2c adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1916] [GtoPdb: 27] [UniProtKB: P18825] | ||||||||
ChEMBL | Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine | B | 4.8 | pKi | 15848.93 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
Angiotensin-converting enzyme 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3736] [GtoPdb: 1614] [UniProtKB: Q9BYF1] | ||||||||
ChEMBL | Inhibition of human recombinant ACE2 at 50 uM using (7Mca-Y-V-A- D -A-P- K(Knp) as a flurogenic substrate measured after 10 mins by fluorescence based analysis | B | 6.14 | pIC50 | 720 | nM | IC50 | J Med Chem (2020) 63: 12256-12274 [PMID:32539378] |
Cyclic GMP-AMP synthase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4105728] [GtoPdb: 3165] [UniProtKB: Q8N884] | ||||||||
ChEMBL | Inhibition of cGAS in human THP-1 cells | B | 4.64 | pIC50 | 23000 | nM | IC50 | Eur J Med Chem (2022) 238: 114480-114480 [PMID:35635952] |
Genome polyprotein in Zika virus (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4523954] [UniProtKB: A0A024AXB9] | ||||||||
ChEMBL | Inhibition of Zika virus NS2B-NS3 protease | B | 4.03 | pKi | 92300 | nM | Ki | Bioorg Med Chem Lett (2020) 30: 126965-126965 [PMID:31980339] |
M1 receptor/Muscarinic acetylcholine receptor M1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL216] [GtoPdb: 13] [UniProtKB: P11229] | ||||||||
ChEMBL | Activity of compound against Muscarinic acetylcholine receptor M1 (CHRM1) by displacement of 3H-QNB | B | 4.81 | pKi | 15488.17 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
M2 receptor/Muscarinic acetylcholine receptor M2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL211] [GtoPdb: 14] [UniProtKB: P08172] | ||||||||
ChEMBL | Activity of compound against Muscarinic acetylcholine receptor M2 (CHRM2) by displacement of 3H-QNB | B | 5.29 | pKi | 5128.61 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
ChEMBL | DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) | B | 5.98 | pKi | 1049 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) | B | 5.53 | pIC50 | 2951 | nM | IC50 | DrugMatrix in vitro pharmacology data |
M3 receptor/Muscarinic acetylcholine receptor M3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL245] [GtoPdb: 15] [UniProtKB: P20309] | ||||||||
ChEMBL | Activity of compound against Muscarinic acetylcholine receptor M3 (CHRM3) by displacement of 3H-QNB | B | 5.32 | pKi | 4786.3 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
M4 receptor/Muscarinic acetylcholine receptor M4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1821] [GtoPdb: 16] [UniProtKB: P08173] | ||||||||
ChEMBL | Activity of compound against Muscarinic acetylcholine receptor M4 (CHRM4) by displacement of 3H-QNB | B | 5.26 | pKi | 5495.41 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
M5 receptor/Muscarinic acetylcholine receptor M5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2035] [GtoPdb: 17] [UniProtKB: P08912] | ||||||||
ChEMBL | Activity of compound against Muscarinic acetylcholine receptor M5 (CHRM5) by displacement of 3H-QNB | B | 4.7 | pKi | 19952.62 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364] | ||||||||
ChEMBL | Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as inhibition of [G-3H]hypoxanthine uptake preincubated for 24 hrs followed by [G-3H]hypoxanthine addition and measured after 18 to 24 hrs by scintillation spectrometry | F | 5.65 | pIC50 | 2217 | nM | IC50 | Eur J Med Chem (2020) 188: 111983-111983 [PMID:31911292] |
ChEMBL | Antimalarial activity against chloroquine-resistant Plasmodium falciparum T996 infected in human erythrocytes assessed as inhibition of [G-3H]hypoxanthine uptake preincubated for 24 hrs followed by [G-3H]hypoxanthine addition and measured after 18 to 24 hrs by scintillation spectrometry | F | 7.67 | pIC50 | 21.5 | nM | IC50 | Eur J Med Chem (2020) 188: 111983-111983 [PMID:31911292] |
σ2/Sigma intracellular receptor 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4105907] [GtoPdb: 2553] [UniProtKB: Q5BJF2] | ||||||||
ChEMBL | Displacement of [3H]-DTG from the Sigma2 receptor | B | 6 | pKi | 1000 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
sigma non-opioid intracellular receptor 1/Sigma opioid receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL287] [GtoPdb: 2552] [UniProtKB: Q99720] | ||||||||
ChEMBL | Displacement of [3H]-pentazocin from the Sigma1 receptor | B | 6.9 | pKi | 125.89 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
TLR7/Toll-like receptor 7 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5936] [GtoPdb: 1757] [UniProtKB: Q9NYK1] | ||||||||
ChEMBL | Antagonist activity at human TLR7 expressed in HEK-Blue cells assessed as inhibition of CL264-induced NFkappaB activation by measuring reduction in SEAP level after overnight incubation using qunati-blue reagent by SEAP reporter gene-based spectrophotometric method | B | 5.07 | pIC50 | 8600 | nM | IC50 | J Med Chem (2020) 63: 4776-4789 [PMID:32302115] |
GtoPdb | Inhibition of hTLR7 R848-induced luciferase reporter gene activation. | - | 5.56 | pIC50 | 2780 | nM | IC50 | Mol Pharmacol (2014) 85: 429-40 [PMID:24342772] |
ChEMBL | Antagonist activity at human TLR7 expressed in HEK-Blue cells assessed as reduction in CL264-induced NF-kappaB levels after 24 hrs by spectrophotometric analysis | B | 6.1 | pIC50 | 800 | nM | IC50 | Eur J Med Chem (2018) 159: 187-205 [PMID:30292896] |
ChEMBL | Antagonist activity at TLR7 (unknown origin) | B | 6.1 | pIC50 | 800 | nM | IC50 | Eur J Med Chem (2021) 210: 112978-112978 [PMID:33189437] |
TLR9/Toll-like receptor 9 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5804] [GtoPdb: 1759] [UniProtKB: Q9NR96] | ||||||||
ChEMBL | Antagonist activity at human TLR9 expressed in HEK-Blue cells assessed as reduction in CpGB-induced NF-kappaB levels after 24 hrs by spectrophotometric analysis | B | 6.96 | pIC50 | 110 | nM | IC50 | Eur J Med Chem (2018) 159: 187-205 [PMID:30292896] |
GtoPdb | Inhibition of hTLR9 CpG2006-induced luciferase reporter gene activation. | - | 7.1 | pIC50 | 80 | nM | IC50 | Mol Pharmacol (2014) 85: 429-40 [PMID:24342772] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]